A Single- and Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease

Trial Profile

A Single- and Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 May 2017

At a glance

  • Drugs LY 3002813 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Dec 2016 Planned End Date changed from 1 Feb 2019 to 1 Jun 2020.
    • 09 Dec 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Jun 2020.
    • 09 Sep 2016 Planned End Date changed from 1 Aug 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top